Naxitamab and Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) Combined With Isotretinoin for Maintenance Treatment of Patients With High-Risk Neuroblastoma in First Complete Response.
Clinical trial NCT06047535 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT06047535
- Sponsor
- SciClone Pharmaceuticals
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 4
- Study type
- INTERVENTIONAL
- Start date
- 2023-10-31
- Primary completion
- 2027-06-15
- Enrollment
- 62
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.